Preventive Maintenance and Repair Service Agreement for Emulate ZOE CM1 and CM2 Culture Modules
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The U.S. Food and Drug Administration (FDA), specifically the Center for Drug Evaluation and Research (CDER), Division of Applied Regulatory Science (DARS), is seeking a contractor for a Preventive Maintenance and Repair Service Agreement for Emulate Zoe CM1 and CM2 Culture Modules. This one-year, Firm Fixed-Price contract aims to ensure the reliability and operational continuity of equipment critical for microphysiological systems (MPS) research. The acquisition is unrestricted full and open competition, not set-aside for small businesses. Offers are due by July 6, 2026, at 1:00 P.M. Central Time.
Scope of Work
The required services include a comprehensive maintenance and repair program for Emulate Zoe CM1 and CM2 culture modules. Key deliverables are:
- One scheduled on-site preventive maintenance visit per instrument annually.
- Unlimited on-site corrective maintenance and repairs.
- All maintenance and repairs must be performed by manufacturer-trained and certified engineers using Original Equipment Manufacturer (OEM) parts.
- Provision of unlimited software and firmware updates.
- Unlimited technical support via phone and email, available Monday through Friday.
- Maintenance coverage extends to specific Emulate MPS chips, including Chip-S1 and Chip-R1 kits.
- Functional Quality Control (QC) testing during each preventive maintenance visit.
- Submission of service record reports following every PM or repair visit.
Contract & Timeline
- Contract Type: Commercial Item - Firm Fixed Price.
- Period of Performance: One (1) year, commencing July 15, 2026, and concluding July 14, 2027.
- Place of Performance: FDA White Oak Campus, Silver Spring, MD 20993.
- Set-Aside: None (Unrestricted Full and Open Competition).
- Offers Due: July 6, 2026, by 1:00 P.M. Central Time.
- Published Date: June 22, 2026.
Evaluation
Award will be made to the lowest priced technically acceptable responsible quoter. Evaluation factors include Technical Capability, Past Performance, and Price. Technical capability and past performance are considered more important than price. Offerors are encouraged to inspect the instruments and site at their own expense.
Submission Requirements
- Quotes must be submitted via email to nick.sartain@fda.hhs.gov.
- Quotes must include the offeror's SAM Unique Entity ID (UEI).
- An Accessibility Conformance Report (ACR) is required for Section 508 compliance.
- Offers must not contain macros.
Additional Notes
The solicitation number for this opportunity is 75F40126Q132585. Payment terms are Net 30 days after government acceptance, processed through the Invoice Processing Platform (IPP). The NAICS Code is 811210, with a Small Business Size Standard of $34 million.